You can buy Lucipirto at the lowest price in the online pharmacy Nextgen.ooo . Pirtobrutinib is a highly selective non-covalent inhibitor of Bruton tyrosine kinase (BTK). Its high selectivity is associated with lower rates of discontinuation due to adverse events and a lower incidence of atrial fibrillation. Unlike covalent BTK inhibitors such as ibrutinib, which bind to the amino acid cysteine ​​481 (Cys481) in the active site of BTK, pirtobrutinib's inhibitory activity is retained even in the presence of Cys481 mutations.
 
Although the mechanisms of resistance to covalent BTK inhibitors are not fully understood, the presence of Cys481 mutations appears to be the most common cause of resistance to covalent BTK inhibitors. However, other mutations can cause resistance to non-covalent BTK inhibitors such as pirtobrutinib. In January 2023, pirtobrutinib was approved by the FDA under the accelerated approval process for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy.